- Home
- APGE vs DEI Comparison
APGE vs DEI Comparison
Compare APGE & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- DEI
- Stock Information
- Founded
- APGE 2022
- DEI 1971
- Country
- APGE United States
- DEI United States
- Employees
- APGE N/A
- DEI N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- DEI Real Estate Investment Trusts
- Sector
- APGE Health Care
- DEI Real Estate
- Exchange
- APGE Nasdaq
- DEI Nasdaq
- Market Cap
- APGE 3.0B
- DEI 3.2B
- IPO Year
- APGE 2023
- DEI 2006
- Fundamental
- Price
- APGE $47.25
- DEI $18.38
- Analyst Decision
- APGE Strong Buy
- DEI Hold
- Analyst Count
- APGE 5
- DEI 7
- Target Price
- APGE $75.20
- DEI $17.43
- AVG Volume (30 Days)
- APGE 366.5K
- DEI 1.6M
- Earning Date
- APGE 11-12-2024
- DEI 11-04-2024
- Dividend Yield
- APGE N/A
- DEI 4.13%
- EPS Growth
- APGE N/A
- DEI N/A
- EPS
- APGE N/A
- DEI N/A
- Revenue
- APGE N/A
- DEI $965,443,000.00
- Revenue This Year
- APGE N/A
- DEI N/A
- Revenue Next Year
- APGE N/A
- DEI N/A
- P/E Ratio
- APGE N/A
- DEI N/A
- Revenue Growth
- APGE N/A
- DEI N/A
- 52 Week Low
- APGE $16.39
- DEI $11.08
- 52 Week High
- APGE $72.29
- DEI $19.59
- Technical
- Relative Strength Index (RSI)
- APGE 35.00
- DEI 51.93
- Support Level
- APGE $57.85
- DEI $18.02
- Resistance Level
- APGE $63.50
- DEI $18.78
- Average True Range (ATR)
- APGE 3.86
- DEI 0.63
- MACD
- APGE -0.90
- DEI -0.07
- Stochastic Oscillator
- APGE 4.97
- DEI 42.38
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About DEI Douglas Emmett Inc.
Douglas Emmett Inc is a real estate investment trust that acquires, develops, and manages office and multifamily properties in Los Angeles, California and Honolulu, Hawaii in the U.S. The company focuses on owning assets in communities with large supply constraints, such as the affluent neighborhoods of Los Angeles. The vast majority of Douglas Emmett's real estate portfolio is comprised of office buildings in Los Angeles. Most of these assets are located in the areas of Sherman Oaks, Woodland Hills, and Beverly Hills in terms of total square feet. Douglas Emmett derives nearly all of its income in the form of rental revenue from tenants. The vast majority of this also comes from its Los Angeles office buildings. The company's major tenants are legal, financial, and entertainment firms.